



## Strategies to enhance the activity of tumor antigen-specific chimeric antigen receptor (CAR) T cells with solid tumors

**Dr. Soldano Ferrone,**

*Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.*

### Abstract

In recent years there has been a growing interest in the use of tumor antigen-specific CAR T cells as an effector mechanism to develop immunotherapy of malignant diseases. The impressive clinical results obtained with CAR T cells with some hematological malignancies have resulted in the FDA approval of some products. On the other hand, tumor antigen-specific CAR T cells have not been so effective with solid tumors thus far. The latter results are believed to be caused at least in part by the escape mechanism utilized by malignant cells to avoid recognition and destruction by immune effector cells. In this presentation I will describe some of the strategies that we are testing in order to counteract the escape mechanisms utilized by malignant cells.

### Corresponding Author

Dr. Soldano Ferrone, MD, PhD Massachusetts General Hospital  
General Hospital Massachusetts General Hospital Phone: (617) 726-6087  
Fax: (617) 726-8623, Email: sferrone@partners.org

### Publications

Dr. Soldano Ferrone, Strategies to enhance the activity of tumor antigen-specific chimeric antigen receptor (CAR) T cells with solid tumors.

19<sup>th</sup> Annual summit on Surgical Oncology  
Webinar, May 19, 2021

---

**Citation:** Dr. Soldano Ferrone, Strategies to enhance the activity of tumor antigen-specific chimeric antigen receptor (CAR) T cells with solid tumors, 19<sup>th</sup> Annual Summit on Surgical Oncology 2471-2671-7:2-02